Glycoprotein IIb/IIIa inhibitors to facilitate percutaneous intervention in st-elevation myocardial infarction

Circulation Journal

Volumn 74, Issue 8, 2010, Pages 1528-1529

  Guzman, Luis A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; RETEPLASE; TENECTEPLASE;

BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; EARLY INTERVENTION; EDITORIAL; ELECTROCARDIOGRAPHY; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEART MUSCLE REPERFUSION; HOSPITALIZATION; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PATIENT TRANSPORT; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; TREATMENT INDICATION; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; HUMANS; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955060409     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0509     Document Type: Editorial

References (15)

1. Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association, Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51: 210-247.
2. Nakayama N, Kimura K, Endo T, Fukui K, Himeno H, Iwasawa Y, et al. Current status of emergency care for ST-elevation myocardial infarction in an urban setting in Japan. Circ J 2009; 73: 484-489.
3. Kiernan TJ, Ting HH, Gersh BJ. Facilitated percutaneous coronary intervention: Current concepts, promises, and pitfalls. Eur Heart J 2007; 28: 1545-1553.
4. Henry TD, Sharkey SW, Burke MN, Chavez IJ, Graham KJ, Henry CR, et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 2007; 116: 721-728.
5. Stone GW, Cox D, Garcia E, Brodie BR, Morice MC, Griffn J, et al. Normal fow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: Analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104: 636-641.
6. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: A meta-analysis. JAMA 2004; 292: 362-366.
7. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myo-cardial infarction (ASSENT-4 PCI): Randomised trial. Lancet 2006; 367: 569-578.
8. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, et al; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358: 2205-2217.
9. Dong L, Zhang F, Shu X. Upstream vs deferred administration of small-molecule glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from Randomized Clinical Trials. Circ J 2010; 74: 1617-1624.
10. Stone GW, Gersh BJ. Facilitated angioplasty: Paradise lost. Lancet 2006; 367: 543-546.
11. Sorajja P, Gersh BJ, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, et al. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 2005; 26: 667-674.
12. Rao SV, Eikelboom JA, Granger CB, Harrington RA, Califf RM, Bassand JP. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1193-1204.
13. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Andersen HR, et al; FINESSE Investigators. 1-year survival in a randomized trial of facilitated reperfusion: Results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. JACC Cardiovasc Interv 2009; 2: 909-916.
14. Herrmann HC, Lu J, Brodie BR, Armstrong PW, Montalescot G, Betriu A, et al; FINESSE Investigators. Beneft of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. JACC Cardiovasc Interv 2009; 2: 917-924.
15. Ross AM, Huber K, Zeymer U, Armstrong PW, Granger CB, Goldstein P, et al. The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: Assessment of the safety and effcacy of a new treatment strategy with percutaneous coronary intervention. JACC Cardiovasc Interv 2009; 2: 925-930.